Inthera Bioscience AG has a total of 12 patent applications. Its first patent ever was published in 2018. It filed its patents most often in United States, Australia and Brazil. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are ARAXES PHARMA LLC, VIIV HEALTHCARE UK LTD and QUANTICEL PHARMACEUTICALS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 2 | |
#2 | Australia | 1 | |
#3 | Brazil | 1 | |
#4 | Canada | 1 | |
#5 | China | 1 | |
#6 | EPO (European Patent Office) | 1 | |
#7 | Israel | 1 | |
#8 | Republic of Korea | 1 | |
#9 | Singapore | 1 | |
#10 | Taiwan | 1 | |
#11 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Cook Cyril | 10 |
#2 | Kessler Ulrich | 10 |
#3 | Johnson Kevin R D | 10 |
#4 | Kaur Matinder | 10 |
#5 | Ullah Farman | 10 |
#6 | Labelle Marc | 10 |
#7 | Vakiti Ramkrishna Reddy | 10 |
#8 | Cattori Valentino | 10 |
#9 | Twibanire Jean-D'Amour K | 9 |
#10 | Twibanire Jean D'Amour K | 1 |
Publication | Filing date | Title |
---|---|---|
CA3085481A1 | 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer |